The editorial team of EPCCS was present at ESC 2018 in Munich, Germany. Read the latest CV news relevant for primary care and hear expert commentaries on the news.
ESC 2018 In this debate, the different viewpoints supporting the European and American Guidelines on Hypertension were fiercely defended, although overlap prevails.
ESC 2018 Dr Allard-Ratick tells about the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.
ESC 2018 In an analysis of four large global studies, higher healthy diet score was related to a lower risk of mortality, MI and stroke. Dr. Mente discusses how the healthy diet score is calculated and talks about the results of these four studies.
ESC 2018 In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.
ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.
ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.
ESC 2018 In adults with CV disease, HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI.
ESC 2018 The NHANES cohort study showed that low-carbohydrate diets increase the risk of mortality in adults, a finding that was validated by a meta-analysis of pooled prospective cohort studies.
ESC 2018 The PURE cohort study showed reduced risk of CV disease and mortality with high-quality diets in general populations worldwide.
ESC 2018 Several studies point towards that both short and long sleep duration, as well as fragmented sleep increase CV risk in healthy subjects, and Indian raga music can improve sleep patterns.
ESC 2018 Key messages of the 2018 ESC/ESH Guidelines for hypertension include no change in the definition of hypertension, treatment for those with high-normal BP and grade I hypertension and initiation of two-drug combination.
ESC 2018 Compared to placebo, lorcaserin was associated with modest and sustained weight loss, and showed CV safety in obese patients with established CV disease or multiple CV risk factors.